Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methyltestosterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 3/20 | 0.72 |
| ▸ | SHBG | P04278 | 9/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 5/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 8/20 | 0.74 |
| ▸ | SERPINA6 | P08185 | 7/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.74 |
| ▸ | BLM | P54132 | 4/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 5/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyltestosterone SCHEMBL29416593 | 1.00 | SHBG (1.00) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| Methyltestosterone SCHEMBL18657 | 1.00 | SHBG (1.00) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| Methyltestosterone SCHEMBL6472960 | 1.00 | SHBG (1.00) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| Methyltestosterone SCHEMBL4442874 | 1.00 | SHBG (1.00) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| Methyltestosterone SCHEMBL18891626 | 1.00 | SHBG (1.00) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| Methyltestosterone SCHEMBL13575766 | 1.00 | SHBG (1.00) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| Methyltestosterone SCHEMBL13965283 | 1.00 | SHBG (1.00) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| Methyltestosterone SCHEMBL13768123 | 1.00 | SHBG (1.00) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| Methyltestosterone SCHEMBL6152059 | 1.00 | SHBG (1.00) | SHBGNR3C1PGRALDH1A1ADRA1A | |
| Methyltestosterone SCHEMBL4575985 | 1.00 | SHBG (1.00) | SHBGNR3C1PGRALDH1A1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115586275-B | Liquid chromatography-tandem mass spectrometry determination method for methyltestosterone in aquatic product | 中国水产科学研究院东海水产研究所 | 2024-09-27 | — | — | CN | disclosed |
| EP-4378483-A1 | USE OF ST-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-115586275-A | Liquid chromatography-tandem mass spectrometry determination method of methyltestosterone in aquatic product | 中国水产科学研究院东海水产研究所 | 2023-01-10 | — | — | CN | disclosed |
| EP-3345594-B1 | SOLUBILIZED FLAVONOID COMPOSITION | TECH INVESTMENTS LC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9730953-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound | VIZURI HEALTH SCIENCES LLC (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730953-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound | VIZURI HEALTH SCIENCES LLC (US) | 2017-08-15 | — | — | US | disclosed |
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | API GENESIS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | API GENESIS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| US-8637569-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds | API GENESIS, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637569-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds | API GENESIS, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2013043529-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2012054090-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUNDS | API GENESIS, LLC (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | AR 2734/4885SHBG 422/4885NR3C1 4485/4885 |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | AR 2734/4885SHBG 422/4885NR3C1 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.